Florbenguane F-18 clinical trials
Also written 18F-MFBG and IRP101.
How each study uses florbenguane F-18 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the florbenguane F-18 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2021 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) (3) · Peking Union Medical College Hospital (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Studies
Open first, then newest update. How each study uses florbenguane F-18 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- 18F-MFBG PET/CT in the Evaluation of Neural Crest TumorRecruitingEarly Phase 1Peking Union Medical College HospitalNCT05069220Written as 18F-MFBG
- Open-Label Study of 18F-mFBG for Imaging NeuroblastomaCompletedPhase 3Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)NCT04724369Written as 18F-MFBG
- Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic InnervationActive, not recruitingPhase 1/2Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)NCT04535193Written as 18F-mFBG for intravenous administration
- 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous SystemWithdrawnPhase 2Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)NCT06233903Written as 18F-mFBG
Codes
What other systems call florbenguane F-18 · ClinicalTrials.gg INT016216
- UNII (FDA) CD7WXM716PFLORBENGUANE F-18One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | CD7WXM716P | FLORBENGUANE F-18 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.